Track Becton, Dickinson and Company — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Becton, Dickinson and Company BDX Open Becton, Dickinson and Company in new tab

154.51 USD
P/E
25.23
EPS
6.13
Yield
2.27%
Safety Score
81
P/B
1.74
ROE
6.96
Beta
0.31
Target Price
196.08 USD
Becton, Dickinson and Company logo

Becton, Dickinson and Company

🧾 Earnings Recap – Q1 2026

Becton, Dickinson and Company reported stronger-than-expected Q1 results for fiscal 2026, driven by disciplined execution and robust growth across key areas, despite challenges in certain segments.

  • Revenues reached $5.3 billion, with new segments growing by 2.5% supported by double-digit growth in biologic drug delivery and advanced tissue regeneration.
  • Adjusted gross margin improved to 53.4%, and adjusted EPS was $2.91, both exceeding expectations.
  • The company is set to close a significant Reverse Morris Trust transaction with Waters, unlocking $4 billion in cash, with plans to allocate $2 billion to share repurchases and $2 billion for debt reduction.
  • Enhanced capital allocation strategy emphasizes share buybacks, consistent dividends, and focused M&A to drive return on invested capital.
📅
Loading chart...
Key Metrics
Earnings dateMay 7, 2026
P/E25.23
EPS6.13
Book Value88.79
Price to Book1.74
Debt/Equity77.28
% Insiders0.399%
Growth
Revenue Growth0.02%
Earnings Growth0.29%
Estimates
Forward P/E11.45
Forward EPS13.51
Target Mean Price196.08
Dividend
Dividend Yield2.27%
Annual dividends3.51 USD
Ex-Div. DateMarch 10, 2026
Payout67.90%
5y avg Yield1.45%

DCF Valuation

Tweak assumptions to recompute fair value for Becton, Dickinson and Company (BDX)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result

Fair Value (DCF)
Current Price
Upside
WACC
Terminal PV
Σ PV of FCFs
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Becton, Dickinson and Company Logo Becton, Dickinson and Company Analysis (BDX)

United States Health Care Official Website Stock

Is Becton, Dickinson and Company a good investment? Becton, Dickinson and Company (BDX) is currently trading at 154.51 USD. Market analysts have a consensus price target of 196.08 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 25.23. This valuation is generally in line with the broader market.

Earnings Schedule: Becton, Dickinson and Company is expected to release its next earnings report on May 7, 2026. The market consensus estimate for Forward EPS is 13.51.

For income investors, Becton, Dickinson and Company pays a dividend yield of 2.27%. With a payout ratio of 68%, the dividend appears sustainable.

Investor FAQ

Does Becton, Dickinson and Company pay a dividend?

Yes, it pays an annual dividend of 3.51 USD (2.27% yield).

What asset class is Becton, Dickinson and Company?

Becton, Dickinson and Company is classified as a Stock. You can compare it against 4 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be May 7, 2026. The company currently has a trailing EPS of 6.13.

Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company has a strategic collaboration with ChemoGLO for the advancement of hazardous drug contamination testing in health care settings to improve the safety of health care workers. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

Exchange Ticker
CNQ (Canada) BDX.CN
NYQ (United States) BDX
LSE (United Kingdom) 0R19.L
SES (Singapore) BDX.SI
Dividend Yield

2.27% (5y avg: 1.45%)

Annual Dividends

3.51 USD

Next ex. div date

March 10, 2026

Payout Ratio

67.90%

Historical Dividends
Year Total Dividends
2027 1.10 USD
2026 4.34 USD
2025 4.17 USD
2024 3.89 USD
2023 3.68 USD
2022 3.52 USD
2021 3.36 USD
2020 3.20 USD
2019 3.10 USD
2018 3.02 USD
2017 2.94 USD
2016 2.71 USD
2015 2.46 USD
2014 2.24 USD
2013 2.03 USD
2012 1.85 USD
2011 1.68 USD
2010 1.89 USD
2009 1.32 USD
2008 1.14 USD
2007 0.98 USD
2006 0.86 USD
2005 0.72 USD
2004 0.60 USD
2003 0.40 USD
2002 0.39 USD
2001 0.38 USD
2000 0.37 USD
1999 0.34 USD
1998 0.51 USD
1997 0.52 USD
1996 0.81 USD
1995 0.82 USD
1994 0.74 USD
1993 0.83 USD
1992 1.20 USD
1991 1.16 USD
1990 1.08 USD
1989 1.00 USD
1988 0.86 USD
1987 0.74 USD
1986 0.50 USD
1985 1.23 USD
1984 1.17 USD
1983 0.86 USD
1973 0.35 USD

Yearly aggregated dividends

Dividends

Becton, Dickinson and Company
Mar 31, 2026 Paid
Dividend
1.05 USD
Becton, Dickinson and Company
Dec 31, 2025 Paid
Dividend
1.05 USD
Becton, Dickinson and Company
Sep 30, 2025 Paid
Dividend
1.04 USD
Becton, Dickinson and Company
Jun 30, 2025 Paid
Dividend
1.04 USD

Historical Split Corporate Actions

Split Date Split Ratio to 1
April 1, 2022 1.030000
Feb. 10, 2026 1.270000
Aug. 21, 1998 2.000000
Aug. 16, 1996 2.000000
March 1, 1993 2.000000
March 3, 1986 2.000000
April 1, 2022 1.020000
Trades
Trade History
No trades yet
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion